Lesèche G, Castier Y, Petit M D, Bertrand P, Kitzis M, Mussot S, Besnard M, Cerceau O
Service de Chirurgie Vasculaire et Thoracique, Hôpital Beaujon, Clichy, France.
J Vasc Surg. 2001 Oct;34(4):616-22. doi: 10.1067/mva.2001.116107.
This prospective, observational study determined the long-term outcome in patients with abdominal aortic infection (primary or prosthetic graft) who were treated with simultaneous aortic/graft excision and cryopreserved arterial allograft reconstruction.
From April 1992 to March 2000, patients with abdominal aortic infection underwent complete or partial excision of the infected aorta/prosthetic graft and cryopreserved arterial allograft reconstruction. Arterial allografts were harvested from multiple organ donors and cryopreserved at -80 degrees C without rate-controlled freezing. The patients were observed for survival, limb salvage, persistence and/or recurrence of infection, and allograft patency. The results were calculated with life-table methods.
During the 8-year study period, 28 consecutive patients (27 men, 1 woman; mean age, 64 years) underwent treatment for abdominal aortic infection (23 graft infections, including 7 graft-enteric fistulas and 5 primary aortic infections). Allograft reconstruction was performed as an emergency procedure in 13 patients (46%). The mean follow-up period was 35.4 months (range, 6-101 months). The overall treatment-related mortality rate was 17.8% (17% for graft infection, 20% for primary aortic infection). The overall 3-year survival was 67%. There was no early or late amputation. There was no persistent or recurrent infection, and none of the patients received long-term (> 3 months) antibiotic therapy. Reoperation for allograft revision, excision, or replacement was necessary in four patients (17%) who were available for examination, with no reoperative perioperative death. The 3-year primary and secondary allograft patency rates were 81% and 96%, respectively.
Our experience with cryopreserved arterial allograft in the management of abdominal aortic infection suggests that this technique seems to be a useful option for treating one of the most dreaded vascular complications.
本前瞻性观察性研究确定了接受同期主动脉/移植物切除及冷冻保存动脉同种异体移植重建治疗的腹主动脉感染(原发性或人工血管感染)患者的长期预后。
1992年4月至2000年3月,腹主动脉感染患者接受了感染主动脉/人工血管的全部或部分切除及冷冻保存动脉同种异体移植重建。动脉同种异体移植物取自多个器官捐献者,并在-80℃下冷冻保存,未进行速率控制冷冻。观察患者的生存情况、肢体保全情况、感染的持续和/或复发情况以及同种异体移植血管的通畅情况。结果采用生命表法计算。
在8年的研究期间,28例连续患者(27例男性,1例女性;平均年龄64岁)接受了腹主动脉感染治疗(23例人工血管感染,包括7例人工血管-肠瘘和5例原发性主动脉感染)。13例患者(46%)作为急诊手术进行了同种异体移植重建。平均随访期为35.4个月(范围6 - 101个月)。总体治疗相关死亡率为17.8%(人工血管感染为17%,原发性主动脉感染为20%)。总体3年生存率为67%。无早期或晚期截肢情况。无持续性或复发性感染,且无一例患者接受长期(>3个月)抗生素治疗。4例可供检查的患者(17%)需要再次手术进行同种异体移植血管翻修、切除或置换,再次手术围手术期无死亡。3年原发性和继发性同种异体移植血管通畅率分别为81%和96%。
我们在冷冻保存动脉同种异体移植治疗腹主动脉感染方面的经验表明,该技术似乎是治疗最可怕的血管并发症之一的有用选择。